Belimumab Drug Asset Due Diligence Report 2026

This Belimumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

132

Registered trials

197

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Belimumab can convert its Monoclonal antibody profile and BAFF biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Belimumab (query alias: belimumab)
Modality / target	Monoclonal antibody; BAFF; BAFF inhibitors
Highest global status	Approved
Originator	GSK Plc
Active developers	GSK Plc, GlaxoSmithKline (Ireland) Ltd., GlaxoSmithKline Trading Services Ltd.

The MCP disease footprint includes Lupus Nephritis, Systemic Lupus Erythematosus, Scleroderma, Systemic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07611214	Phase 4	Recruiting	150	To assess the efficacy of LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response: Proportion of patients with complete renal response at 24 weeks
NCT07138898	Phase 2	Recruiting	80	Incidence of wound complications
NCT07340463	Phase 2	Recruiting	50	Complete Renal Response (CRR) Rate at Month 6

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

THE USE OF BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS IN REAL LIFE SETTING: ANALYSIS OF DRUG DISCONTINUATION AND FLARES FROM A MULTICENTRIC, NATIONWIDE ITALIAN COHORT (BeRLiSS-JS 2.0)

Not Applicable; n=312; evaluation: Positive. Reported fields: Flare incidence rates = articular flares had a rate of 13.61 per 100 PY (95% CI 11.11 - 16.5), cutaneous flares 9.91 (7.79 - 12.42), hematological flares 5.28 (3.77 - 7.2), renal 3.57 (2.35 - 5.19), constitutional 2.11 (1.21 - 3.43), serositic 1.98 (1.11 - 3.27), and neuropsychiatric 0.79 (0.29 - 1.73)

PERIPHERAL BLOOD GENE EXPRESSION AS A BIOMARKER OF SUSTAINED RESPONSE TO B-CELL THERAPY IN SJÖGREN’S DISEASE

Phase 2; n=37; evaluation: Positive. Reported fields: Differentially expressed genes = 199.0 gene

FIVE-YEAR SAFETY OF BELIMUMAB IN SLE: INSIGHTS FROM THE GLOBAL, PROSPECTIVE, OBSERVATIONAL SABLE REGISTRY

Not Applicable; n=2967; evaluation: Positive. Reported fields: AE(serious infections) = 11.0 per 100 person-years

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Belimumab addresses Lupus Nephritis, Systemic Lupus Erythematosus, Scleroderma, Systemic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2000-03-01	CAT grant of five exclusive product licenses during 2002 (three to HGSI, one to Amgen and one to Wyeth Research)	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO